Big pharma, Partnering, Pharma

BMS signs an optional pharma deal with Galecto worth $444 million

Posted on 04 November 2014

Tags: , , ,

Bristol-Myers Squibb signed a pharma deal for an exclusive option to acquire Galecto Biotech and gain worldwide rights to its lead asset TD139.

TD139 is a Phase I inhaled inhibitor of galectin-3 being developed to treat idiopathic pulmonary fibrosis and other pulmonary fibrotic conditions.

The deal was valued at up to $444 million, a sum that includes an option fee, an option exercise fee, and subsequent payments tied to clinical and regulatory milestones.

Bristol-Myers Squibb can exercise the option to acquire Galecto at any time following the execution of the transaction agreement but no later than 60 days following completion of a Phase Ib trial.

The companies have agreed on preclinical studies and a Phase I development plan that will be carried out by Galecto during the option period.

For further deal information visit Current Agreements (subscription required)

Related

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

View: Partnering Scorecard in CP Insight– view top life science partnering deals by value

View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply